Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233086 | 0.85 | HRH3 (0.59) | HRH3KCNH2CA2CHKACHRNB2 | |
| SCHEMBL2829052 | 0.85 | HRH3 (0.63) | HRH3KCNH2 | |
| SCHEMBL8176884 | 0.85 | HRH3 (0.63) | HRH3KCNH2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2798402 | 0.83 | HRH3 (0.92) | HRH3KCNH2 | |
| SCHEMBL24433453 | 0.82 | HRH3 (0.86) | HRH3KCNH2 | |
| SCHEMBL2798303 | 0.82 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL13232434 | 0.80 | HRH3 (0.58) | HRH3KCNH2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL8173191 | 0.78 | HRH3 (0.52) | HRH3KCNH2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL3262640 | 0.78 | HRH3 (0.90) | HRH3KCNH2 | |
| SCHEMBL2799922 | 0.78 | HRH3 (0.55) | HRH3KCNH2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | HRH3 2630/4885KCNH2 4742/4885CA2 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.